Advertisement

Topics

Latest "The European Federation of Biotechnology" News Stories

17:03 EST 16th November 2018 | BioPortfolio

Here are the most relevant search results for "The European Federation of Biotechnology" found in our extensive news archives from over 250 global news sources.

More Information about The European Federation of Biotechnology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about The European Federation of Biotechnology for you to read. Along with our medical data and news we also list The European Federation of Biotechnology Clinical Trials, which are updated daily. BioPortfolio also has a large database of The European Federation of Biotechnology Companies for you to search.

Showing "European Federation Biotechnology" News Articles 1–25 of 9,800+

Friday 16th November 2018

EMA committee recommends approval of Bristol─Myers Squibb's Opdivo plus low─dose Yervoy as first─line treatment for RCC

Bristol─Myers Squibb Company has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (nivolumab)


EU Panel Backs Expanding Ribociclib Approval in HR+/HER2- Breast Cancer

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended expanding the approval of ribociclib (Kisqali) in women with HR+/HER2-negative breast cancer to include use in combination with fulvestrant (Faslodex). 

Former PM David Cameron joins Northern Businesses Showcasing UK Life Science

The world’s largest biotech gathering taking place in San Diego this week, the BIO Convention, has seen the North of England showcase its offer to more than 60 countries - and former Prime Minister David Cameron talk down fears over what Brexit will mean for the sector. Four of the seven sponsors of the Department for International Trade's UK stand at BIO come from the North; including the A...


NanoSphere Announces $2.25 Million Financing for Rapid Expansion of Cannabis Product Line

NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce a non-brokered private placement of up to CAD $2,250,000. The proceeds will be used to expand the award-winning Evolve Formulas cannabis products into more markets in the US, Canada, and outside of North America. Funds will also be used to develop new products, increase ...

CENTOGENE Announces CentoPharma, World’s First Platform for Targeted Patient Cohort Identification

Provides intelligent access to a unique repository of genetic, biochemical and clinical information from global patient cohorts affected by rare hereditary diseases CENTOGENE today announced the launch of CentoPharma 1.0, the world’s first CE labeled platform for targeted patient cohort identification. A tailored approach to targetin...

Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the closing of its initial public offering of 4,600,000 shares of common stock, ...

Gut Microbiota Regulated by Hydrogen Peroxide in Lactation

NewsA recent animal study published in The FASEB Journal explores the uncharted territory of how the gut microbiome develops in infancy.

Agilent Expands Cell Analysis R&D Capabilities in Ireland

New facility incorporates recently acquired Luxcel Biosciences Agilent Technologies Inc. (NYSE: A) today announced the opening of a new, purpose-built extension to its Little Island, Cork facility in Ireland. The campus will focus on developing advanced technologies for the analysis of live-cells in real-time. The expanded state-of-the-...

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas

-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma- -FDA Approval Based on Results from the Phase 3 ECHELON-2 Clinical Trial; Data to be Presented at the 2018 ASH Annual Meeting- -Application Approved Less Than Two Weeks After Submission Under FDA Real-Time Oncology Review Pilot Program-

Puma Biotechnology: Risky Investment

Kidney Organoids Harbor Rogue Cell Types

A few rotten apples may indeed spoil the whole bunch—if the bunch happens to be an organoid, a cluster of cells grown in the laboratory to mimic an organ. Kidney organoids, for example, are used to study how real kidneys work and respond to newly developed treatments. But if kidney organoids contain wayward non-kidney cells, […] The post Kidney Organoids Harbor Rogue Cell Types appeared fi...

Conjugated Nanoparticles Improve Chemo Drug Delivery

Improving how chemotherapy is delivered to cancer cells is a major concern for researchers and drug manufacturers. One of the big issues with chemotherapy is that most treatment approaches focus on the tumor itself without paying significant attention to the microenvironment surrounding the tumor. Now, investigators at Purdue University have developed new technology aimed at […] The post Con...

Trial results show compound makes radiotherapy more effective

A trial has shown that radiotherapy is more effective when levels of ropidoxuridine in a patients' body reach a certain level... The post Trial results show compound makes radiotherapy more effective appeared first on European Pharmaceutical Review.

Brown Fat Makes an Attractive Target for New Approaches to Treating Obesity

Scientists report that brown fat interacts with the gut hormone secretin in mice to relay nutritional signals about fullness to the brain during a meal. Study reinforces our understanding of a long-suspected role of brown adipose tissue, a type of body fat known to generate heat when an animal is cold, in the control of food intake. The post Brown Fat Makes an Attractive Target for New Approaches ...

Triple-Negative Breast Cancer in Mice Inhibited by Migraine Drug

A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that drives the development of aggressive basal-like breast cancer. The post Triple-Negative Breast Cancer in ...

CHMP positive opinion on apalutamide for patients with non-metastatic castration-resistant prostate cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen...

AstraZeneca’s Imfinzi Fails 2nd Primary Endpoint in Phase III MYSTIC Trial

AstraZeneca and its MedImmune subsidiary acknowledged today that their marketed anticancer treatment Imfinzi™ (durvalumab) failed the second of two primary endpoints in a Phase III trial designed to assess the programmed death-ligand 1 (PD-L1) blocking antibody alone and in combination with the companies’ anti-CTLA4 antibody tremelimumab in a form of non-small cell lung cancer (NSCLC). The [&...

EMA Curtails Use of Fluoroquinolone, Quinolone Antibiotics

The occurrence of disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics has led the European Medicines Agency (EMA) to restrict or suspend their use. News Alerts

Four Drugs Set For EU Approval, EMA Holds Fire On Pacritinib

The European Medicines Agency this week recommended marketing approval for four medicines, including a drug for use in countries outside the...   

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Us...

Progress in genetic testing of embryos stokes fears of designer babies – Medical Xpress

Medical XpressProgress in genetic testing of embryos stokes fears of designer babiesMedical XpressRecent announcements by two biotechnology companies have stoked fears that designer babies could soon be an option for those who can afford to pick and choose which features they want for their offspring. The companies, MyOme and Genomic ...and more

Government must guarantee EU doctors’ rights after Brexit, says BMA

The BMA has urged the government to formally guarantee the rights of European citizens in the event of the UK leaving the EU without an agreement next March, after a poll of doctors from other...

Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness The positive opinion is the result of a 10-year partnership between the Drugs for Neglected Diseases initiative (DNDi), Sanofi and African partners Fexinidazole will support international efforts to eliminate sleeping sickness, a

$VRTX Receives European CHMP Positive Opinion for ORKAMBI® for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

$VRTX Receives European CHMP Positive Opinion for ORKAMBI® for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Recordati Rare Diseases Canada Inc. Announces the Canadian Launch of PANHEMATIN®

Recordati Rare Diseases Canada Inc., a biopharmaceutical company providing orphan therapies for patients with rare diseases, today announced the commercial launch of PANHEMATIN®, the first prescription medication approved by Health Canada for the treatment of recurrent attacks of acute intermittent porphyria (AIP). This press release features multimedia. V...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks